BiotechTube
Argá Medtech

Argá Medtech

Lausanne, Switzerland· Est.
argamedtech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Argá Medtech is a private, pre-revenue medical device innovator targeting the significant unmet need in cardiac ablation for atrial fibrillation. The company's technology platform centers on a unique pulsed field ablation (PFA) system that employs a sine wave energy waveform, which it claims offers safety, speed, and efficacy advantages over existing thermal and pulsed-field systems. Operating in the large and growing cardiovascular device market, Argá aims to improve long-term patient outcomes by providing a more versatile and controlled ablation solution. The company is in the development stage, advancing its proprietary system and catheter toward clinical validation.

Cardiovascular

Technology Platform

Proprietary Pulsed Field Ablation (PFA) system utilizing a novel sine wave energy delivery waveform for non-thermal cardiac tissue ablation.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global epidemic of Atrial Fibrillation creates a large and growing addressable market for safer, more effective ablation technologies.
The rapid adoption of first-generation PFA systems validates the non-thermal approach and opens a door for next-generation, potentially superior technologies like Argá's sine wave platform.
There is significant potential for partnership or acquisition by large medtech players active in electrophysiology.

Risk Factors

The company faces intense competition from well-funded incumbents with approved PFA systems.
Its novel sine wave technology is unproven in clinical settings and carries the risk of failing to demonstrate expected advantages.
As a pre-revenue, private company, it is dependent on raising capital to fund expensive development and regulatory pathways.

Competitive Landscape

The cardiac ablation market is dominated by large medical device companies using thermal energy (RF, Cryo). The PFA segment is now competitive with approved systems from Medtronic (PulseSelect) and Boston Scientific (FARAPULSE), and J&J is advancing its system. Several other private companies are developing alternative PFA technologies. Argá competes on the basis of its unique sine wave waveform, claiming potential advantages in safety and efficacy over these existing pulsed and thermal modalities.

More companies in Switzerland →